Phosphatidylserine-targeting antibodies and T cell function in HIV-1 infection
Official title: Defining the Impact of Phosphatidylserine-Targeting Antibodies on T Cell Function in HIV-1 Infection
Funded at Rutgers Biomedical and Health Sciences · NIH-11470783 · Data updated 2026-11-12
This NIH grant will explore how antibodies that target phosphatidylserine affect immune cells in people living with HIV on ART.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | September 1, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $431,750 |
| NIH project number | 1R21AI203589-01 |
| Project ID | NIH-11470783 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults living with HIV-1 who are on stable ART regimens and have persistent immune activation or specific antibody profiles related to antiphospholipid antibodies.
✕Less likely to help
Patients without HIV, those not on ART, or individuals without immune activation markers may not benefit from these findings.
What this research studies
In people with HIV who are on antiretroviral therapy, persistent immune activation and inflammation remain a problem. This study looks at antibodies that bind phosphatidylserine and how they influence T cells and overall immune responses. It uses human cells and immune measurements to understand whether these antibodies contribute to either beneficial antiviral effects or harmful immune activation. The goal is to identify host-directed strategies that could reduce inflammation and improve immune health in HIV-infected individuals.
Why it matters
Potential benefit: If successful, the research could lead to new ways to lessen chronic inflammation and improve immune function in people with HIV.
How similar studies have gone: Prior work has shown that PS-reactive antibodies can influence HIV infection dynamics in lab settings, but human studies are needed to confirm relevance.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Choudhary, Alok Kumar — Rutgers Biomedical and Health Sciences
- Study coordinator: Choudhary, Alok Kumar
Related research
Other NIH-funded projects on the same topics.
-
BEAT-HIV: a collaborative effort to cure HIV with immunotherapy
A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.
-
Ribosomal frameshifting in HIV-1 infection and its effects on inflammation and brain health
A study at the University of Rochester will explore how HIV-1 may change human cell machinery to boost its own replication and cause inflammation and brain-related problems.
-
Targeting NLRP3 inflammasome to protect HIV patients from stroke
A small NIH grant will explore whether HIV infection makes stroke worse and whether blocking a brain inflammation pathway (NLRP3) could protect brain tissue.
-
Reprogramming tissue immune cells (macrophages) to target hidden HIV
Trying small drug molecules to reprogram tissue immune cells so infected cells die and hidden HIV is reduced in people living with HIV.
-
EHD4 protein and HIV-1 infection: a new potential antiviral target
A study to understand how the human protein EHD4 affects HIV-1 infection and whether it could be targeted to develop better antiviral therapies.
-
Understanding Brain Cell Growth in People with HIV and Methamphetamine Exposure
This research explores how HIV and methamphetamine use together might change how new brain cells grow, aiming to understand related thinking problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.